Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer

BMC Urology

Volumn 12, Issue , 2012, Pages

  Reis, Sabrina Thalita ^a   Leite, Katia Ramos M ^a   Piovesan, Luís Felipe ^a   Pontes Junior, José ^a   Viana, Nayara Izabel ^a   Abe, Daniel Kanda ^a   Crippa, Alexandre ^a   Moura, Caio Martins ^a   Adonias, Sanarelly Pires ^a   Srougi, Miguel ^a   Dalloglio, Marcos Francisco ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bladder cancer; Diagnosis; Gene expression; Matrix metalloproteinase; Prognosis

Indexed keywords

GELATINASE B; INTERLEUKIN 8; MATRIX METALLOPROTEINASE 14; PROTEIN; PROTEIN RECK; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYSTECTOMY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; PROGNOSIS; PROSTATE HYPERTROPHY; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; GPI-LINKED PROTEINS; HUMANS; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84862165679     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-12-18     Document Type: Article

References (24)

1. Global Cancer Statistics, 2011. Jemal A, Bray F, Center MM, Cancer J Clin. 2011 61 69 90 10.3322/caac.20107
2. FGFR3 and Ras gene mutationsare mutually exclusive genetic events in urothelial cell carcinoma. Jebar AH, Hurst CD, Tomlinson DC, Oncogene 2005 24 5218 5225 10.1038/sj.onc.1208705 15897885 (Pubitemid 41192438)
3. Bladder Cancer. Borden LS, Clark PE, Hall MC, Curr Opin Oncol 2005 17 275 280 10.1097/01.cco.0000156985.47984.9e 15818174 (Pubitemid 40586170)
4. Metalloproteinases and tissue inhibitors of metalloproteinases. Toi M, Ishigaki S, Tominaga T, Breast Cancer Res Treat 1998 52 113 124 10.1023/A:1006167202856 10066076 (Pubitemid 29056089)
5. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. Henriet P, Blavier L, Declerck YA, APMIS 1999 107 111 119 10.1111/j.1699-0463.1999.tb01533.x 10190287 (Pubitemid 29133530)
6. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Nawrocki B, Polette M, Marchand V, Monteau M, Gillery P, Tournier JM, Int J Cancer 1997 72 556 564 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.0.CO;2-P 9259391 (Pubitemid 27356153)
7. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE, Kelly JD, Br J Cancer 2006 Feb 27 94 569 577 10.1038/sj.bjc.6602931 (Pubitemid 43289762)
8. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM, Eur Urol 2007 52 1388 1396 10.1016/j.eururo.2007.04.006 17466450 (Pubitemid 47445978)
9. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenase in colorectal cancer. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Ballewill F, Cancer Res 1996 56 190 196 8548762 (Pubitemid 26010399)
10. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Kodate M, Kasai T, Hashimoto H, Yabumoto K, Iwata Y, Manobe H, Pathol Int 1997 47 461 469 10.1111/j.1440-1827.1997.tb04525.x 9234385 (Pubitemid 27280170)
11. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M, Am J Pathol 1997 151 1105 1113 9327744 (Pubitemid 27424320)
12. Analysis of gene expression profile in gastric cancer cells stimulated with Helicobacter pylori isogenic strains. Yuan JP, Li T, Chen HB, Li ZH, Yang GZ, Hu BY, Shi XD, Tong SQ, Li YX, Guo XK, J Med Microbiol 2004 53 965 974 10.1099/jmm.0.45634-0 15358818 (Pubitemid 39391964)
13. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ, Bar-Eli M, Clin Cancer Res 2003 9 3167 3175 12912969 (Pubitemid 36993279)
14. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Cho NH, Shim HS, Rha SY, Kang SH, Hong SH, Choi YD, Hong SJ, Cho SH, Eur Urol 2003 44 560 566 10.1016/S0302- 2838(03)00362-2 14572755 (Pubitemid 37328632)
15. Prognostic and predictive potential molecular biomarkers in colon cancer. Nastase A, Pslaru L, Niculescu AM, Ionescu M, Dumitracu T, Herlea V, Dima S, Gheorghe C, Lazar V, Popescu I, Chirurgia (Bucur). 2011 106 2 177 185
16. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an information prognostic indicator for colorectal cancer. Takeuchi T, Hisanaga M, Nagao M, et al. Clin Cancer Res 2004 10 5572 5579 10.1158/1078-0432.CCR-03-0656 15328199 (Pubitemid 39100498)
17. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH, Am J Pathol 1996 149 273 282 8686751 (Pubitemid 26230998)
18. Angiogenesis and non-small cell lung cancer. Cox G, Jones JL, Walker RA, Steward WP, OByrne KJ, Lung Cancer 2000 27 81 100 10.1016/S0169-5002(99)00096-3 10688491 (Pubitemid 30067629)
19. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Takahashi C, Sheng Z, Horan TP, et al. Proc Natl Acad Sci U S A 1998 95 13221 13226 10.1073/pnas.95.22.13221 9789069 (Pubitemid 28509552)
20. Involvement of the Sp1 site in ras-mediated down-regul ation of the RECK metastasis suppressor gene. Sasahara RM, Takahashi C, Noda M, Biochem Biophys Res Commun 1999 264 668 675 10.1006/bbrc.1999.1552 10543990
21. Involvement of histone deacetylation in ras-induced down regulation of metastasis suppressor RECK. Chang HC, Liu LT, Hung WC, Cell Signal 2004 16 675 679 10.1016/j.cellsig.2003.11.001 15093608 (Pubitemid 38490549)
22. HER-2/neu represses the metastasis suppressorRECK via ERK and Sp transcription factor to promote cell invasion. Hsu MC, Chang HC, Hung WC, J Biol Chem 2006 281 4718 4725 16377629
23. The membrane anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Oh J, Takahashi R, Kondo S, et al. Cell 2001 107 789 800 10.1016/S0092-8674(01)00597-9 11747814 (Pubitemid 34033671)
24. The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo. Chang CK, Hung WC, Chang HC, J Cell Mol Med 2008 2008 12 12 ahead of print